^
    Back
    Association details:
    Biomarker:LMO2 overexpression
    Cancer:T Cell Non-Hodgkin Lymphoma
    Drug:AiRuiYi (fluzoparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    EHA 2023
    Title:

    PARP INHIBITORS ARE EFFECTIVE IN NATURAL KILLER/T CELL LYMPHOMA VIA THE EXPRESSION OF LMO2

    Published date:
    05/11/2023
    Excerpt:
    Furthermore, fluzoparib, one of the PARPis, caused the accumulation of DNA damage, and LMO2 deficiency reduced the sensitivity of NKTCL cells to PARPis. Additionally, NKTCL patients with high LMO2 expression may have better progression-free survival and overall survival. Finally, the combination of fluzoparib and cisplatin exhibited significant synergistic effects both in vitro and in vivo.
    Secondary therapy:
    cisplatin